3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
39
Ovarian Neoplasms
29
Multiple Myeloma
16
Neoplasms
9
Recurrence
8
Lymphoma
8
Fallopian Tube Neoplasms
8
Triple Negative Breast Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
7
Hodgkin Disease
7
Carcinoma, Ovarian Epithelial
7
Lymphoma, Non-Hodgkin
6
Sarcoma
5
Neoplasm Metastasis
5
Burkitt Lymphoma
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Lung Neoplasms
2
Liver Neoplasms
2
Leukemia
2
Leiomyosarcoma
2
Kidney Neoplasms
2
Endometrial Neoplasms
2
Disease Progression
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
liposomal doxorubicin
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled